Posts
A once-daily triple-drug HIV regimen
containing an experimental integrase inhibitor performed better in suppressing
the virus than Atripla in a Phase III trial, developers of the new drug say.
The trial pitted dolutegravir in combination with two older HIV drugs against
the three-drug Atripla.
Results from the SINGLE trial found
88 percent of patients taking the dolutegravir-based regimen achieved
undetectable virus at 48 weeks, compared with 81 percent for Atripla patients.
Dolutegravir is being developed by Japanese partner Shionogi & Co. and ViiV
Healthcare, a partnership of UK-based GlaxoSmithKline and US-based Pfizer.
Complete trial results will be
presented at an upcoming scientific meeting. In April, the first set of study
results showed dolutegravir was as effective as twice-daily Isentress. Four
Phase III studies due for reporting this year are designed to accompany
regulatory filings in support of the drug.
Dolutegravir’s low-milligram dosing
could make it easier to include in a fixed-dose combination pill, and there
could be fewer side effects because a booster is not required.
The Friends of AIDS Foundation is
dedicated to enhancing the quality of life for HIV positive individuals and
empowering people to make healthy choices to prevent the spread of the HIV
virus. To learn more about The Friends of AIDS Foundation, please visit: http://www.friendsofaids.org.
TOGETHER WE REMAIN STRONG!
